311 related articles for article (PubMed ID: 31250134)
1. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.
Stienen S; Rossignol P; Barros A; Girerd N; Pitt B; Zannad F; Ferreira JP
Clin Res Cardiol; 2020 Feb; 109(2):194-204. PubMed ID: 31250134
[TBL] [Abstract][Full Text] [Related]
2. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP; Duarte K; Montalescot G; Pitt B; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Rossignol P; Vincent J; Zannad F
Clin Res Cardiol; 2018 Jan; 107(1):49-59. PubMed ID: 28852839
[TBL] [Abstract][Full Text] [Related]
3. Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction.
Stienen S; Ferreira JP; Bär C; Thum T; Barros A; Pitt B; Girerd N; Rossignol P; Zannad F
Int J Cardiol; 2021 Jun; 332():35-37. PubMed ID: 33676945
[TBL] [Abstract][Full Text] [Related]
4. Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post-ST-Segment-Elevation Myocardial Infarction.
Wong EC; Fordyce CB; Wong G; Lee T; Perry-Arnesen M; Mackay M; Singer J; Cairns JA; Turgeon RD
J Am Heart Assoc; 2021 Jul; 10(14):e019167. PubMed ID: 34227405
[TBL] [Abstract][Full Text] [Related]
5. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
6. Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.
Toda K; Kasama S; Toyama T; Kasahara M; Kurabayashi M
J Nucl Cardiol; 2022 Oct; 29(5):2325-2335. PubMed ID: 34272676
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
[TBL] [Abstract][Full Text] [Related]
8. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
[TBL] [Abstract][Full Text] [Related]
9. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
[TBL] [Abstract][Full Text] [Related]
10. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
11. Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.
Ferreira JP; Barros A; Pitt B; Montalescot G; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Leite-Moreira A; Vincent J; Rossignol P; Zannad F
Clin Res Cardiol; 2018 Dec; 107(12):1192-1195. PubMed ID: 30264283
[No Abstract] [Full Text] [Related]
12. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Montalescot G; Pitt B; Lopez de Sa E; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Vincent J; Zannad F; ;
Eur Heart J; 2014 Sep; 35(34):2295-302. PubMed ID: 24780614
[TBL] [Abstract][Full Text] [Related]
13. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
15. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.
Beygui F; Van Belle E; Ecollan P; Machecourt J; Hamm CW; Lopez De Sa E; Flather M; Verheugt FWA; Vicaut E; Zannad F; Pitt B; Montalescot G
Heart; 2018 Nov; 104(22):1843-1849. PubMed ID: 29695512
[TBL] [Abstract][Full Text] [Related]
16. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
O'Keefe JH; Abuissa H; Pitt B
Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
